Belgium bans Ozempic prescription for weight loss until summer
The ban is due to a shortage of Novo Nordisk’s diabetes medicine.
BY MARKETWIRE
Belgian authorities have temporarily banned doctors from prescribing Novo Nordisk’s diabetes drug Ozempic for the treatment of obesity.
The ban is due to a shortage of Ozempic, according to a royal decree from Belgium’s Official Gazette, according to Reuters.
Ozempic can still be prescribed for the treatment of type 2 diabetes. The active ingredient in Ozempic, Semaglutide, is the same as in Novo Nordisk’s weight loss drug Wegovy, which has not yet been launched in Belgium.
The ban provisionally runs until June 2024.
(Translated using DeepL with additional editing by Mads Oddershede)
